Mild hemophilia A is caused by a missense mutation in the FVIII gene that is responsible for a decrease in the FVIII:C to between 5% and 40%. The development of FVIII inhibitors has been reported in 3-13% of patients with mild hemophilia. Genetic risk factors for the development of inhibitors in mild hemophilia have been investigated. In the present study, we encountered a case of mild hemophilia with an FVIII inhibitor and identified the mutation responsible: a novel Phe595Cys mutation in the FVIII gene. In addition, this study showed that the inhibitor recognized exogenous wild-type FVIII and autologous mutant FVIII.
CITATION STYLE
Yamanouchi, J., Tokumoto, D., Ikeda, Y., Maruta, M., Kaneko, M., Hato, T., & Yasukawa, M. (2018). Development of an fviii inhibitor in a mild hemophilia patient with a phe595cys mutation. Internal Medicine, 57(21), 3179–3182. https://doi.org/10.2169/internalmedicine.1145-18
Mendeley helps you to discover research relevant for your work.